Hybrid cytokines as hematopoietic growth factors

D. E. Williams, L. S. Park, Hal Broxmeyer, L. Lu

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

A large body of in vitro and in vivo data suggests that combinations of cytokines provide the most effective mechanism for stimulating multilineage acceleration of hematopoiesis. Creation of a granulocyte-macrophage colony-stimulating factor (GM-CSF)/interleukin 3 (IL-3) fusion protein has yielded a single therapeutic which has enhanced biological activity in comparison to the individual cytokines from which it is composed. In vivo studies with this fusion protein (PIXY321) suggest that it may provide a means to accelerate both neutrophil and platelet recovery in clinical settings in which hematopoiesis is suppressed. The biology of PIXY321 and the potential for other fusion proteins is discussed.

Original languageEnglish (US)
Pages (from-to)542-547
Number of pages6
JournalInternational Journal of Cell Cloning
Volume9
Issue number6
StatePublished - 1991

Fingerprint

Intercellular Signaling Peptides and Proteins
Interleukin-3
Hematopoiesis
Cytokines
Proteins
Granulocyte-Macrophage Colony-Stimulating Factor
Neutrophils
Blood Platelets
Therapeutics
In Vitro Techniques

ASJC Scopus subject areas

  • Cell Biology

Cite this

Hybrid cytokines as hematopoietic growth factors. / Williams, D. E.; Park, L. S.; Broxmeyer, Hal; Lu, L.

In: International Journal of Cell Cloning, Vol. 9, No. 6, 1991, p. 542-547.

Research output: Contribution to journalArticle

Williams, DE, Park, LS, Broxmeyer, H & Lu, L 1991, 'Hybrid cytokines as hematopoietic growth factors', International Journal of Cell Cloning, vol. 9, no. 6, pp. 542-547.
Williams, D. E. ; Park, L. S. ; Broxmeyer, Hal ; Lu, L. / Hybrid cytokines as hematopoietic growth factors. In: International Journal of Cell Cloning. 1991 ; Vol. 9, No. 6. pp. 542-547.
@article{d55b3582ceb6411f8ff450d8832ff178,
title = "Hybrid cytokines as hematopoietic growth factors",
abstract = "A large body of in vitro and in vivo data suggests that combinations of cytokines provide the most effective mechanism for stimulating multilineage acceleration of hematopoiesis. Creation of a granulocyte-macrophage colony-stimulating factor (GM-CSF)/interleukin 3 (IL-3) fusion protein has yielded a single therapeutic which has enhanced biological activity in comparison to the individual cytokines from which it is composed. In vivo studies with this fusion protein (PIXY321) suggest that it may provide a means to accelerate both neutrophil and platelet recovery in clinical settings in which hematopoiesis is suppressed. The biology of PIXY321 and the potential for other fusion proteins is discussed.",
author = "Williams, {D. E.} and Park, {L. S.} and Hal Broxmeyer and L. Lu",
year = "1991",
language = "English (US)",
volume = "9",
pages = "542--547",
journal = "Stem Cells",
issn = "1066-5099",
publisher = "AlphaMed Press",
number = "6",

}

TY - JOUR

T1 - Hybrid cytokines as hematopoietic growth factors

AU - Williams, D. E.

AU - Park, L. S.

AU - Broxmeyer, Hal

AU - Lu, L.

PY - 1991

Y1 - 1991

N2 - A large body of in vitro and in vivo data suggests that combinations of cytokines provide the most effective mechanism for stimulating multilineage acceleration of hematopoiesis. Creation of a granulocyte-macrophage colony-stimulating factor (GM-CSF)/interleukin 3 (IL-3) fusion protein has yielded a single therapeutic which has enhanced biological activity in comparison to the individual cytokines from which it is composed. In vivo studies with this fusion protein (PIXY321) suggest that it may provide a means to accelerate both neutrophil and platelet recovery in clinical settings in which hematopoiesis is suppressed. The biology of PIXY321 and the potential for other fusion proteins is discussed.

AB - A large body of in vitro and in vivo data suggests that combinations of cytokines provide the most effective mechanism for stimulating multilineage acceleration of hematopoiesis. Creation of a granulocyte-macrophage colony-stimulating factor (GM-CSF)/interleukin 3 (IL-3) fusion protein has yielded a single therapeutic which has enhanced biological activity in comparison to the individual cytokines from which it is composed. In vivo studies with this fusion protein (PIXY321) suggest that it may provide a means to accelerate both neutrophil and platelet recovery in clinical settings in which hematopoiesis is suppressed. The biology of PIXY321 and the potential for other fusion proteins is discussed.

UR - http://www.scopus.com/inward/record.url?scp=0025934197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025934197&partnerID=8YFLogxK

M3 - Article

C2 - 1770228

AN - SCOPUS:0025934197

VL - 9

SP - 542

EP - 547

JO - Stem Cells

JF - Stem Cells

SN - 1066-5099

IS - 6

ER -